# Group 6: Rare Disease Healthcare Support (Solo Project)

## Project Title
Healthcare Support for Patients with Rare Diseases in Hong Kong

## Overview
This solo project examines how Hong Kong's healthcare system supports patients with rare diseases, particularly focusing on drug access, treatment costs, and policy challenges.

## Google Doc
- **Public Info Curation**: [Link](https://docs.google.com/document/d/1IplYThZIHmhCy0a8tcycNCAmia80iBRFTGT8La2ZUoU/edit)

---

## Research Focus

### Key Questions

1. How does Hong Kong define and identify rare diseases?
2. What drugs are available for rare disease patients?
3. How do patients access expensive treatments?
4. What are the gaps in current policy and support?

---

## Sources Already Collected

### Source 1: Carrie Lam's Promise (2017)
- **URL**: https://www.scmp.com/news/hong-kong/health-environment/article/2117508/carrie-lam-promises-patients-she-will-personally
- **Key Fact**: CE Carrie Lam promised to personally help SMA patients access nusinersen drug
- **Issue Highlighted**: Drug registration system delays access to life-saving treatments

### Source 2: Spare Machine Trust (2012)
- **URL**: https://www.scmp.com/news/hong-kong/article/1095238/spinal-muscular-atrophy-patients-put-trust-spare-machines
- **Key Fact**: Families rely on charitable trust for spare medical equipment
- **Issue Highlighted**: Expensive equipment not readily available; patients risk hospitalization

### Source 3: Marcus Ng's Surgery (2021)
- **URL**: https://www.scmp.com/news/hong-kong/health-environment/article/3149289/brave-hong-kong-boy-rare-disorder-faces-his
- **Key Fact**: 10-year-old SMA patient with only 10% lung function faces high-risk spinal surgery
- **Issue Highlighted**: Progressive nature of condition requires ongoing medical intervention

### Source 4: LegCo Q&A on Rare Disease Support (2024)
- **URL**: https://www.info.gov.hk/gia/general/202406/12/P2024061200662p.htm
- **Key Facts**:
  - HA has databases for 35 uncommon disorders, expanding to 207
  - "1+" mechanism for fast-tracking new drug registration launched Nov 2023
  - Some patients buy drugs from Mainland at 5% of HK prices
  - Age limit (25) for SMA drug subsidies questioned

---

## Key Issues Identified

| Issue | Details |
|-------|---------|
| Drug Access | Expensive drugs not registered in HK; long approval process |
| Cost | Some drugs cost patients over $50,000/month |
| Age Limits | SMA patients lose drug subsidies after age 25 |
| Equipment | Life-sustaining machines expensive and not readily available |
| Cross-Border | Patients considering Mainland for cheaper drugs |

---

## Policy Context

### "1+" Mechanism
- Launched: November 1, 2023
- Purpose: Fast-track registration of new drugs for life-threatening diseases
- Allows drugs approved by one recognized regulatory authority to be registered in HK

### Hospital Authority Drug Formulary
- Established mechanism for reviewing new drugs
- Considers: safety, efficacy, cost-effectiveness
- Has safety net for subsidies

---

## Next Steps

- [ ] Complete Task 3.1: Google site-specific search
- [ ] Complete Task 3.2: Add more sources to Google Doc
- [ ] Identify specific improvement recommendations
- [ ] Compare with international rare disease policies

---

## Resources

- Families of SMA Charitable Trust: http://www.fsma.org.hk/
- Hospital Authority: https://www.ha.org.hk/
- Rare Disease Hong Kong: https://www.rdhk.org/

---

*Last Updated: January 29, 2026*
